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Abstract. The aim of the present study was to compare the
survival outcomes for patients with metastatic renal cell carci‑
noma (mRCC) who underwent laparoscopic cytoreductive
nephrectomy (CN) vs. open CN vs. targeted therapy (TT) alone
at our institution. A retrospective chart review was performed
at our institution for patients who underwent CN prior to TT
(laparoscopic, n=48; open, n=48) or who were deemed unfit for
surgery and received TT alone (n=36), between January 2007
and December 2012. Kaplan‑Meier estimated survival and Cox
proportional hazards analyses were performed. Laparoscopic
CN was associated with significantly longer survival compared
with open CN or TT alone (median survival 24 vs. <12 months,
respectively; P<0.01). On multivariate analysis, laparoscopic
CN was an independent predictor of survival [hazard ratio
(HR)=0.48, P<0.01), controlling for preoperative risk factors,
while survival was similar between open CN and TT alone
(HR=0.85, P=0.54). In our experience, laparoscopic CN appears
to be a significant predictor of survival in mRCC. Selection
bias of the surgeon for patients with improved survival may
account for clinical variables that were otherwise difficult to
quantify. For patients who were not candidates for laparoscopic
CN, open CN did not confer a survival benefit over TT alone,
while it was associated with increased morbidity.
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Introduction
The role of cytoreductive nephrectomy (CN) in patients with
metastatic renal cell carcinoma (mRCC) was initially defined
during the era of open surgery and first‑generation immuno‑
therapy (e.g., interleukin‑2 and interferon α) (1‑3). For some
patients with mRCC a survival benefit from CN was not
achieved, while there was increased morbidity as a result of
surgery; therefore, risk factors for prognosis were defined in
order to aid in surgical candidate selection (4,5). Since then, the
landscape of systemic therapy for mRCC has changed drasti‑
cally with targeted therapy, such as tyrosine kinase inhibitors
and mammalian target of rapamycin (mTOR) inhibitors, as the
mainstays of treatment (6,7) The benefit of CN in the era of
targeted therapy (TT) was subsequently defined (8), and noted
to be most pronounced for selected patients (9‑11).
In parallel with the advances in systemic therapy for
mRCC, the paradigm for CN has shifted from an open to
a laparoscopic approach (12). The oncological safety of
laparoscopic CN was established during the first‑generation
immunotherapy era, and has expanded into the TT era (13‑15).
The reduced convalescence associated with laparoscopic
surgery is particularly important for patients with mRCC,
as this may reduce their time to systemic therapy initiation.
However, the interplay between laparoscopic CN and patient
survival has not been studied in the TT era.
The aim of the present study was to compare the survival
outcomes of laparoscopic CN, open CN and TT alone (for
patients who were deemed unfit for surgery) at our institution
during the TT era.
Patients and methods
Patient information. After obtaining Institutional Review
Board approval, all mRCC patients who received systemic TT
between January 2007 and December 2012 at our institution
(n=132) were retrospectively reviewed. TT patients were
defined as those who received tyrosine kinase inhibitors,
mTOR inhibitors and vascular endothelial growth factor
inhibitors. We identified a total of 96 patients who received
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CN prior to TT, and 36 patients who received TT alone, as they
were deemed unfit for CN. Laparoscopic CN was performed in
50% (48/96) of the patients, with the remainder receiving open
CN. The histological subtypes for the CN patients included
71% clear cell, 17% sarcomatoid, 7% papillary type II and 5%
other types. Subtype classification for the patients receiving
TT alone could not be determined, as the patients were diag‑
nosed clinically or on biopsy of their metastatic site, which
presented pathological limitations.
Patient clinical variables were collected, including age,
adult comorbidity evaluation score (16) and Karnofsky
performance status score. The preoperative risk stratifica‑
tion variables for CN described by Culp et al and validated
by our institutional experience were also collected (10,11).
These variables included: i) Serum albumin below laboratory
normal, ii) clinical T3 or T4 disease, iii) presence of liver
metastasis, iv) symptomatic metastasis, v) retroperitoneal
lymphadenopathy and vi) supradiaphragmatic lymphade‑
nopathy. Survival data were gathered using available medical
records and the Social Security death index, with final query
on August 31, 2017.
Statistical analysis. Kaplan‑Meier‑estimated overall survival
(OS) was compared among laparoscopic CN, open CN and
TT alone. The OS end‑point was reached by 100% (36/36)
of patients in the TT cohort, 98% (47/48) of patients in the
open CN cohort, and 96% (46/48) of patients in the laparo‑
scopic CN cohort. Multivariate Cox proportional hazards
analysis was also performed adjusting for age, Karnofsky
performance status score and preoperative risk stratification
variables. To calculate statistical significance, the χ2 test was
used for categorical variables and the Student's t‑test was used
for continuous variables, with P<0.05 considered to indicate
statistically significant differences. All statistical analyses
were completed using R software, version 3.2.2.
Results
Patient characteristics. Patient baseline clinical and tumor
characteristics are provided in Table I. The open CN, lapa‑
roscopic CN and TT alone groups differed significantly in
the proportion of patients with Karnofsky performance status
score ≤60%, mean number of preoperative risk stratification
variables, proportion of patients with serum albumin ≤3.5 g/dl,
clinical stage >T3, symptomatic metastasis and supradiaphrag‑
matic lymphadenopathy (P<0.01 in all cases).
The survival of patients undergoing laparoscopic CN is superior to that of the other two cohorts. Kaplan‑Meier‑estimated
survival curves are provided in Fig. 1. The median OS was
23.9 months in the laparoscopic CN group (2 patients censored),
10.8 months in the open CN group (1 patient censored), and
10.7 months in the TT alone group (P<0.01). Multivariate Cox
proportional hazards analysis identified laparoscopic CN as
an independent predictor of survival (hazard ratio=0.48, 95%
confidence interval: 0.31‑0.74, P<0.01), controlling for age,
Karnofsky performance status score and the number of preop‑
erative risk stratification variables.
Median survival was examined with subsets of the open CN
and laparoscopic CN cohorts, which are provided in Table II.

Figure 1. Kaplan‑Meier estimated overall survival for open CN, laparoscopic
CN, and targeted therapy alone. CN, cytoreductive nephrectomy; TKI, tyro‑
sine kinase inhibitor.

When excluding patients with Karnofsky performance status
score ≤60%, the median survival remained significantly greater
for the laparoscopic CN group (27 vs. 11 months, respec‑
tively; P<0.01). When additionally excluding patients with ≥3
preoperative risk stratification variables, the median survival
remained significantly greater for the laparoscopic CN group
(28 vs. 11 months, respectively; P<0.01). When additionally
excluding patients with clinical stage T3 or T4 disease, the
median survival remained significantly greater for the laparo‑
scopic CN group (29 vs. 12 months, respectively; P<0.01).
Discussion
In the present study, laparoscopic CN was found to be associated
with a significant increase in OS compared to open CN and TT
alone, independent of patient and tumor characteristics. To the
best of our knowledge, this is the first direct examination of the
CN approach and its impact on survival. It was demonstrated
that the difference in median survival between laparoscopic
and open CN was ~12 months, while open CN and TT alone
exhibited similar survival. Furthermore, this survival benefit
in favor of laparoscopic over open CN persisted in multivariate
and subset analyses.
The initial studies of laparoscopic CN focused on its
non‑inferiority compared with conventional open CN,
with limited numbers of patients and limited oncological
follow‑up (13‑15). The studies by Rabets et al and Eisenberg et al
included substantially fewer patients compared with the present
study (n=64, n=27 and n=132, respectively), and only included
1‑year estimated survival (14,15). Furthermore, these studies
were performed in the era of first‑generation immunotherapy
(e.g., interleukin‑2 and interferon α), which makes their study
findings difficult to compare to those of the present study and
contemporary practice for mRCC. Additionally, the use of lapa‑
roscopic nephrectomy and, thus, laparoscopic CN, has markedly
increased since then (12). Zlatev et al reported a decrease in open
CN from 77 to 66% between 2003 and 2015, within the Premier
Hospital Database. Associated with this increase in utilization,
they also found that laparoscopic CN significantly reduced the
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Table I. Patient baseline clinical and tumor characteristics.
Variables

Open CN,
n=48

Laparoscopic CN,
n=48

TT alone,
n=36

P‑value

Mean age (SD), years
Mean ACE score (SD)
Karnofsky performance status score <60, n (%)
Mean preoperative risk stratification variables (SD)
Albumin <3.5 g/dl, n (%)
Clinical stage >T3, n (%)
Liver metastasis, n (%)
Symptomatic metastasis, n (%)
Retroperitoneal LN, n (%)
Supradiaphragmatic LN, n (%)

56.4 (9.2)
1.2 (0.8)
3/48 (6.3)
2.6 (1.1)
17/48 (35)
32/48 (67)
10/48 (21)
20/48 (42)
22/48 (46)
20/48 (42)

58.8 (12.0)
1.0 (1.0)
7/48 (14.6)
2.0 (1.3)
10/48 (21)
17/48 (35)
9/48 (19)
29/48 (60)
15/48 (31)
13/48 (27)

57.8 (10.4)
1.3 (1.0)
12/36 (33)
3.1 (1.1)
20/36 (56)
14/36 (39)
11/36 (31)
27/36 (75)
20/36 (56)
22/36 (61)

0.54
0.32
<0.01
<0.01
<0.01
<0.01
0.41
<0.01
0.08
<0.01

CN, cytoreductive nephrectomy; TT, targeted therapy; SD, standard deviation; ACE, adult comorbidity evaluation; LN, lymphadenopathy.

Table II. Median survival for subsets of patients receiving open and laparoscopic CN.

Patient subsets
Entire cohort
Karnofsky <60% excluded
>3 risk factors excluded
Clinical stage >T3 excluded

Median survival
‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Open CN, n (months)
Laparoscopic CN, n (months)
48 (10.8)
45 (11.1)
22 (11.4)
11 (12.1)

48 (23.9)
41 (26.9)
29 (28.3)
24 (28.9)

P‑value
<0.01
<0.01
<0.01
<0.01

CN, cytoreductive nephrectomy.

rate of blood transfusion [odds ratio (OR)=0.46] and length of
hospital stay (OR=0.50) (17). Similarly, Gershman et al found
that laparoscopic CN significantly reduced the length of hospital
stay (OR= 0.12) and, more importantly, significantly reduced the
time to initiation of TT (OR=5.1), when compared to open CN
in their institutional experience (n=294) (18).
Although a number of studies have focused on the periop‑
erative outcomes following laparoscopic CN, comparatively
few studies have been published on the OS of patients receiving
laparoscopic CN in the TT era. Nunez Bragayrac et al reported
the survival of a contemporary (2001‑2013) pooled cohort of
mRCC patients (n=120) receiving laparoscopic CN at three
high‑volume cancer centers. The median survival was reported
as 25.7 months, with a 3‑year survival rate of 35% (19). A
similar survival rate was found our laparoscopic CN cohort,
with a median survival of 23.9 months and a 3‑year survival
rate of 26%. However, with no comparator arm, the study by
Nunez Bragayrac et al did not demonstrate the comparative
survival benefit of laparoscopic CN over open CN or TT alone.
To the best of our knowledge, the present study is the first to
directly compare OS following laparoscopic CN, open CN and
TT alone in the TT era. Although previous studies have demon‑
strated the survival benefit of CN over TT alone (8‑11,20,21),
many have argued that the survival benefit is a result of surgeon
selection bias (22,23). Given the retrospective nature of these

studies (including our own), surgeon selection bias cannot be
eliminated, and likely contributes to the survival differences
seen in patients who receive CN. An example of surgeon
selection bias impacting retrospective studies of survival was
published by Shuch et al, who demonstrated that the OS in
patients receiving partial nephrectomy in the Medicare popula‑
tion was improved over non‑cancer controls (24).
Although some patients may not tolerate the insufflation
associated with laparoscopic surgery and some tumors (i.e.,
higher clinical T stage) were not amenable to a laparoscopic
approach, we observed that laparoscopic CN was associated
with improved survival independent of these factors from
a statistical standpoint (multivariate model), as well as in a
subset analysis. However, as a retrospective study, confounding
variables associated with surgical selection bias could not
be eliminated. Furthermore, the survival benefit observed
with laparoscopic CN was likely a result of unaccounted for
variables, or the value of surgeon cognitive bias in clinical
decision‑making. Despite our single‑institution study being
adequately powered to detect statistically significant differ‑
ences between treatment groups, and being significantly larger
than previously published studies on the same subject, the
overall size of the study (n=132) remains limited. Of note, by
including patients between 2007 and 2012, nearly all patients in
the study (129/132=98%) had reached their survival end‑points.
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In conclusion, it was herein demonstrated that laparoscopic
CN was an independent and significant predictor of survival in
mRCC when compared to open CN or TT alone. In our experi‑
ence, for patients who were not candidates for laparoscopic
CN, open CN did not confer a survival benefit over TT alone.
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